Leniolisib

Leniolisib
Clinical data
Trade names	Joenja
Other names	CDZ173
AHFS/Drugs.com	Monograph
MedlinePlus	a623016
License data	US DailyMed: Leniolisib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	L03AX22 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Identifiers
CAS Number	1354690-24-6; as salt: 1354691-97-6;
DrugBank	DB16217;
ChemSpider	52083264;
UNII	L22772Z9CP;
KEGG	D11158; as salt: D11159;
ChEMBL	ChEMBL3643413;
PDB ligand	9NQ (PDBe, RCSB PDB);
Chemical and physical data
Formula	C21H25F3N6O2
Molar mass	450.466 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)N1CC[C@@H](C1)NC1=C2CN(CCC2=NC=N1)C1=CN=C(OC)C(=C1)C(F)(F)F;
	InChI InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1; Key:MWKYMZXCGYXLPL-ZDUSSCGKSA-N;

Leniolisib (INN), sold under the brand name Joenja, is a medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is a kinase inhibitor that is taken by mouth.

The most common side effects include headache, sinusitis, and atopic dermatitis.

Leniolisib was approved for medical use in the United States in March 2023. It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.